PMID- 36420005
OWN - NLM
STAT- MEDLINE
DCOM- 20221125
LR  - 20230130
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 10
DP  - 2022
TI  - Association of metabolic dysfunction-associated fatty liver disease, type 2 
      diabetes mellitus, and metabolic goal achievement with risk of chronic kidney 
      disease.
PG  - 1047794
LID - 10.3389/fpubh.2022.1047794 [doi]
LID - 1047794
AB  - BACKGROUND: Although type 2 diabetes mellitus (T2DM) plays a significant role in 
      the association between metabolic dysfunction-associated fatty liver disease 
      (MAFLD) and chronic kidney disease (CKD), how T2DM development and glycemic 
      deterioration affect CKD and its renal function indicators, estimated glomerular 
      filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), remains 
      unknown. We aimed to assess the association between MAFLD, along with T2DM, and 
      risk of CKD, and then evaluate the effect of metabolic goal achievement in MAFLD 
      on the risk of CKD. METHODS: In this cross-sectional study, 5,594 participants 
      were included. Multivariate logistic regression and linear regression were used 
      to examine the association between MAFLD with its T2DM status and metabolic goal 
      achievement and risk of CKD, as well as eGFR and UACR. RESULTS: The MAFLD group 
      had a higher prevalence of CKD (16.2 vs. 7.6%, P < 0.001) than the non-MAFLD 
      group. MAFLD was independently associated with an increased risk of CKD (odds 
      ratio [OR]: 1.35, 95% CI: 1.09-1.67) and increased eGFR and UACR. Among the three 
      MAFLD subtypes, only the T2DM subtype exhibited significant associations with 
      increased risk of CKD (OR: 2.85, 95% CI: 2.24-3.63), as well as increased eGFR 
      and UACR. Glycemic deterioration in MAFLD was dose-dependently associated with an 
      increased risk of CKD (P-trend < 0.001). Achieved metabolic goals in MAFLD 
      decreased the risk of CKD, eGFR, and UACR; MAFLD with 2 or 3 achieved metabolic 
      goals was not significantly associated with the risk of CKD (OR: 0.81, 95% CI: 
      0.59-1.12) and albuminuria. CONCLUSION: MAFLD was independently associated with 
      an increased risk of CKD, as well as increased eGFR and UACR. This association is 
      strongly driven by T2DM status. Glycemic deterioration in MAFLD was 
      dose-dependently associated with an increased risk of CKD. Achieved metabolic 
      goals in MAFLD decreased the risk of CKD by reducing the risk of albuminuria.
CI  - Copyright (c) 2022 Su, Chen, Xiao, Du, Xue, Feng and Ye.
FAU - Su, Weitao
AU  - Su W
AD  - School of Public Health, Fujian Medical University, Fuzhou, China.
FAU - Chen, Minhui
AU  - Chen M
AD  - Department of Ultrasonography, Fuqing Hospital, Fuqing, China.
FAU - Xiao, Ling
AU  - Xiao L
AD  - School of Public Health, Fujian Medical University, Fuzhou, China.
FAU - Du, Shanshan
AU  - Du S
AD  - School of Public Health, Fujian Medical University, Fuzhou, China.
FAU - Xue, Lihua
AU  - Xue L
AD  - Department of Ultrasonography, Fuqing Hospital, Fuqing, China.
FAU - Feng, Ruimei
AU  - Feng R
AD  - School of Public Health, Fujian Medical University, Fuzhou, China.
FAU - Ye, Weimin
AU  - Ye W
AD  - School of Public Health, Fujian Medical University, Fuzhou, China.
AD  - Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
      Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221107
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Albuminuria
MH  - Cross-Sectional Studies
MH  - Goals
MH  - *Renal Insufficiency, Chronic/epidemiology/etiology
MH  - *Liver Diseases
PMC - PMC9676964
OTO - NOTNLM
OT  - albuminuria
OT  - chronic kidney disease
OT  - estimated glomerular filtration rate
OT  - metabolic dysfunction-associated fatty liver disease
OT  - metabolic goal achievement
OT  - type 2 diabetes mellitus
OT  - urine albumin-to-creatinine ratio
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/25 06:00
MHDA- 2022/11/26 06:00
PMCR- 2022/11/07
CRDT- 2022/11/24 02:30
PHST- 2022/09/18 00:00 [received]
PHST- 2022/10/17 00:00 [accepted]
PHST- 2022/11/24 02:30 [entrez]
PHST- 2022/11/25 06:00 [pubmed]
PHST- 2022/11/26 06:00 [medline]
PHST- 2022/11/07 00:00 [pmc-release]
AID - 10.3389/fpubh.2022.1047794 [doi]
PST - epublish
SO  - Front Public Health. 2022 Nov 7;10:1047794. doi: 10.3389/fpubh.2022.1047794. 
      eCollection 2022.